460 related articles for article (PubMed ID: 34508654)
1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
[TBL] [Abstract][Full Text] [Related]
2. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
[TBL] [Abstract][Full Text] [Related]
3. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
Takaura K; Ando H; Ganoza ER
Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
[TBL] [Abstract][Full Text] [Related]
7. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
[TBL] [Abstract][Full Text] [Related]
8. Epcoritamab: First Approval.
Frampton JE
Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
[TBL] [Abstract][Full Text] [Related]
9. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20
Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
[TBL] [Abstract][Full Text] [Related]
10. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
[No Abstract] [Full Text] [Related]
11. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Godfrey J; Mei M; Chen L; Song JY; Bedell V; Budde E; Armenian S; Puverel S; Nikolaenko L; Chen R; Daniels S; Kennedy N; Peters L; Rosen ST; Forman SJ; Popplewell LL; Kwak LW; Herrera AF
Haematologica; 2024 Feb; 109(2):533-542. PubMed ID: 37470137
[TBL] [Abstract][Full Text] [Related]
12. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bartlett NL; Assouline S; Giri P; Schuster SJ; Cheah CY; Matasar M; Gregory GP; Yoon DH; Shadman M; Fay K; Yoon SS; Panizo C; Flinn I; Johnston A; Bosch F; Sehn LH; Wei MC; Yin S; To I; Li CC; Huang H; Kwan A; Penuel E; Budde LE
Blood Adv; 2023 Sep; 7(17):4926-4935. PubMed ID: 37067952
[TBL] [Abstract][Full Text] [Related]
13. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
[TBL] [Abstract][Full Text] [Related]
14. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
[TBL] [Abstract][Full Text] [Related]
15. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
Kopmar NE; Quach K; Gooley TA; Martino CH; Cherian S; Percival MM; Halpern AB; Ghiuzeli CM; Oehler VG; Abkowitz JL; Walter RB; Cassaday RD
JAMA Oncol; 2024 May; ():. PubMed ID: 38722664
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Haverkos B; Alpdogan O; Baiocchi R; Brammer JE; Feldman TA; Capra M; Brem EA; Nair S; Scheinberg P; Pereira J; Shune L; Joffe E; Young P; Spruill S; Katkov A; McRae R; Royston I; Faller DV; Rojkjaer L; Porcu P
Blood Adv; 2023 Oct; 7(20):6339-6350. PubMed ID: 37530631
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
[TBL] [Abstract][Full Text] [Related]
18. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.
Phillips T; Lugtenburg P; Kalsekar A; Mutebi A; Wang A; Blaedel J; Kosa K; Martin S; Sacchi M; Kilavuz N; Thieblemont C
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e78-e87.e2. PubMed ID: 38151388
[TBL] [Abstract][Full Text] [Related]
19. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE; Olszewski AJ; Assouline S; Lossos IS; Diefenbach C; Kamdar M; Ghosh N; Modi D; Sabry W; Naik S; Mehta A; Nakhoda SK; Smith SD; Dorritie K; Jia T; Pham S; Huw LY; Jing J; Wu H; Ead WS; To I; Batlevi CL; Wei MC; Chavez JC
Nat Med; 2024 Jan; 30(1):229-239. PubMed ID: 38072960
[TBL] [Abstract][Full Text] [Related]
20. CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study.
Xiao X; Liu H; Qiu X; Chen P; Li X; Wang D; Song G; Cheng Y; Yang L; Qian W
EClinicalMedicine; 2024 Apr; 70():102516. PubMed ID: 38444429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]